Precision Oncology: What It Is and Who It Helps

Precision oncology is an approach to cancer care that uses information about a person’s tumor, such as genetic changes and biomarkers, to help guide treatment decisions. It can help some patients receive therapies that are more closely matched to their cancer’s biology.

Overview

Precision oncology is a cancer care approach that uses detailed information about a tumor to help guide diagnosis, treatment, and follow-up. Instead of relying only on the organ where the cancer began, doctors also study the tumor’s genetic changes, proteins, and other molecular signals. This may show whether a cancer is likely to respond to a specific medicine or whether a different treatment plan may be more suitable.

Many cancers that look similar under a microscope can behave differently because of their molecular makeup. Precision oncology aims to understand those differences. In practice, this often means testing a tumor for biomarkers, gene mutations, or other features that can help match a patient to targeted therapy, immunotherapy, or a clinical trial when appropriate.

It is important to understand that precision oncology does not always mean a single “custom-made” treatment. For some people, testing identifies a clear target and directly affects care. For others, results may confirm that standard treatments remain the best option. Even when testing does not reveal an actionable finding, it can still provide useful information about prognosis or future treatment choices.

How Precision Oncology Works

The process usually begins with a sample of tumor tissue collected during a biopsy or surgery. A laboratory may analyze this sample using molecular profiling or genomic testing. In some cases, a blood test called a liquid biopsy can look for fragments of tumor DNA circulating in the bloodstream. These tests help identify biomarkers such as mutations, gene fusions, protein expression patterns, or other changes that may influence treatment response.

Doctors then interpret these findings together with standard pathology, imaging, stage of disease, symptoms, and overall health. This is why precision oncology is often discussed in multidisciplinary cancer meetings, where oncologists, pathologists, radiologists, surgeons, and genetic specialists review the results together. The goal is not only to find a target, but also to decide whether that target is clinically meaningful and whether treatment is safe and appropriate for the individual patient.

Common examples include identifying mutations that can be treated with specific drugs, or biomarkers that suggest a patient may respond to immunotherapy. In many cases, molecular testing complements established treatments rather than replacing them. A patient may still need chemotherapy, radiation therapy, or cancer surgery as part of a complete care plan.

Who Precision Oncology May Help

Precision oncology may be especially helpful for patients with advanced cancers, cancers that have returned after treatment, or tumors known to have actionable biomarkers. It is commonly used in some types of lung cancer, breast cancer, colorectal cancer, melanoma, ovarian cancer, and certain blood cancers. In these situations, molecular testing may uncover treatment options that are more specifically matched to the tumor’s biology.

It can also be valuable in cancers that are difficult to classify, rare tumors, or cases where standard treatment options are limited. Sometimes testing helps doctors refine the diagnosis itself. For example, molecular findings may distinguish between subtypes of cancer that need different treatment strategies.

However, precision oncology is not equally useful in every case. Some early-stage cancers can be treated effectively with well-established methods without extensive molecular testing. In addition, some tumors do not have a known actionable alteration, and some identified changes may not yet have an approved targeted therapy. This is why the value of precision oncology depends on the cancer type, stage, prior treatments, and the quality of available evidence.

Benefits and Limitations

The main benefit of precision oncology is that it may make treatment more personalized. When a tumor has a targetable feature, therapy may be chosen more precisely than with a one-size-fits-all approach. This can help some patients avoid ineffective treatments, identify clinical trial opportunities, or receive therapies with a better chance of benefit for their specific cancer type.

Another advantage is that precision oncology may improve understanding of how a tumor is likely to behave over time. Certain biomarkers can help estimate whether a cancer may be more aggressive, whether it may respond to immunotherapy, or whether resistance to treatment is developing. Repeating testing later in the course of illness may sometimes reveal new changes in the tumor.

At the same time, there are important limitations. Not all test results lead to a treatment decision, and not every detected mutation is clinically actionable. Tumors can also be biologically complex, meaning one biopsy may not capture every part of the cancer. Results may take time, and in urgent situations treatment may need to begin before full profiling is complete. Precision oncology works best when expectations are realistic and decisions are guided by experienced specialists.

Diagnosis and Testing

Precision oncology depends on accurate diagnosis and careful testing. The first step is confirming the type of cancer through pathology, imaging, and clinical evaluation. Molecular testing is then selected based on the cancer type and the question doctors are trying to answer. Some patients need single-biomarker tests, while others may benefit from broader next-generation sequencing panels that assess many genes at once.

Testing may include:

• Tumor tissue analysis from biopsy or surgery
• Blood-based liquid biopsy in selected cases
• Immunohistochemistry to measure protein markers
• Tests for gene mutations, amplifications, or fusions
• Markers that may predict response to immunotherapy

Doctors may also consider whether genetic counseling is needed. Some molecular findings suggest an inherited cancer predisposition rather than a change found only in the tumor. In that setting, patients and families may benefit from further assessment. A clear explanation of what a test can and cannot show is important before results are used to make treatment decisions.

Because testing technology is evolving quickly, interpretation matters as much as the laboratory report itself. Results should be reviewed in the context of symptoms, cancer stage, prior treatment history, and current guidelines. This helps ensure that treatment choices are evidence-based and appropriate for the individual.

Treatment Options Guided by Precision Oncology

When testing reveals a relevant biomarker, treatment may be adjusted accordingly. One common option is targeted therapy, which aims at a specific molecular change helping the cancer grow. Another is immunotherapy, which may be considered when biomarkers suggest the immune system could be effectively activated against the tumor. In some situations, molecular results help doctors choose among standard therapies rather than introducing an entirely new one.

Precision oncology can also support treatment sequencing. For example, if a patient has already received standard therapy, new molecular information may help identify the next step. In other cases, repeat testing may explain why a treatment has stopped working and whether resistance mutations have appeared. This can be especially relevant in metastatic disease, where treatment planning often changes over time.

Clinical trials are another important part of precision oncology. Some patients may qualify for research studies testing new targeted medicines or new ways of using existing drugs. Trial enrollment depends on many factors, including the exact biomarker, cancer type, previous treatments, and overall health. Patients can ask their oncologist whether a trial is suitable and available.

Even with highly individualized planning, precision oncology remains part of comprehensive cancer care. Symptom control, nutrition, emotional support, rehabilitation, and careful monitoring are all essential. Treatment decisions should balance potential benefit with quality of life, side effects, and the patient’s own goals and preferences.

Questions to Ask and When to See a Doctor

Patients may wish to ask whether their cancer type commonly benefits from molecular testing, what sample will be used, how long results may take, and whether the findings could change treatment. It is also reasonable to ask whether a result may affect family members, whether repeat testing might be needed later, and whether there are relevant clinical trials. Clear communication can help patients understand the role of precision oncology without creating unrealistic expectations.

A person should speak with a doctor promptly if they have a new cancer diagnosis, a cancer that has returned, or cancer that is not responding as expected to treatment. Precision oncology is not an emergency intervention by itself, but early discussion can be helpful because some tests require adequate biopsy material and careful planning before therapy begins.

Patients who already have a diagnosis such as lung cancer or breast cancer may find that biomarker testing is an important part of modern treatment planning. For international patients who need evaluation, Acibadem International’s multidisciplinary specialists at JCI-accredited hospitals diagnose and treat cancer using evidence-based approaches that may include precision oncology when appropriate.

Frequently asked questions

What is precision oncology in simple terms?

Precision oncology is a way of treating cancer based on the specific biological features of a person’s tumor. Doctors use test results such as gene changes or biomarkers to help choose treatments that may be more suitable for that cancer.

Is precision oncology the same as personalized medicine?

The terms are closely related and are often used together. In cancer care, precision oncology usually refers to using molecular and genetic information from a tumor to guide more personalized treatment decisions.

Does every cancer patient need molecular testing?

No. Molecular testing is very important for some cancers and less helpful for others. Whether it is recommended depends on the cancer type, stage, available treatments, and whether test results are likely to change care.

Can precision oncology cure cancer?

Precision oncology is a tool for choosing treatment, not a guaranteed cure. In some patients it can lead to very effective therapy, but outcomes vary depending on the cancer type, stage, and how the tumor responds.

What is a liquid biopsy?

A liquid biopsy is a blood test that looks for tumor-related DNA or other cancer signals circulating in the bloodstream. It can be useful in certain situations, especially when tissue is hard to obtain, but it does not replace all standard biopsy methods.

What happens if testing finds no actionable mutation?

This is common and does not mean treatment options are gone. Standard treatments such as surgery, chemotherapy, radiation therapy, hormone therapy, or supportive care may still be the best approach, and future testing may sometimes be considered later.

References

• World Health Organization
• National Cancer Institute
• American Society of Clinical Oncology
• European Society for Medical Oncology
• National Comprehensive Cancer Network

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.